美金刚对神经原纤维病理脑脊液生物标志物的影响。
Effects of memantine on cerebrospinal fluid biomarkers of neurofibrillary pathology.
机构信息
Center for Brain Health, Department of Psychiatry, New York University School of Medicine, 145 East 32nd Street, 5th Floor, New York, NY10016, USA.
出版信息
J Alzheimers Dis. 2009;18(3):509-13. doi: 10.3233/JAD-2009-1183.
Abstract
Previous studies showed that memantine inhibits tau hyperphosphorylation in vitro. In this study, phosphorylated tau (P-tau) and total tau (T-tau) were measured before and after 6 month treatment with memantine in 12 subjects ranging from normal cognition with subjective memory complaints, through mild cognitive impairment to mild Alzheimer's disease. Thirteen non-treated individuals served as controls. Treatment was associated with a reduction of P-tau in subjects with normal cognition. No treatment effects were seen among impaired individuals, suggesting that longer treatment time may be necessary to achieve biomarker effect in this group.
摘要
先前的研究表明美金刚可抑制体外 Tau 过度磷酸化。本研究在 12 例受试者中观察了 6 个月的美金刚治疗前后，他们的认知状态从正常伴有主观记忆主诉，到轻度认知障碍，再到轻度阿尔茨海默病。13 例未接受治疗的个体作为对照。治疗与认知正常受试者的 P-tau 减少相关。在认知障碍者中未观察到治疗效果，这表明在该组中可能需要更长的治疗时间才能达到生物标志物效应。
相似文献
1
Effects of memantine on cerebrospinal fluid biomarkers of neurofibrillary pathology.
J Alzheimers Dis. 2009;18(3):509-13. doi: 10.3233/JAD-2009-1183.
2
Memantine improves cognition and reduces Alzheimer's-like neuropathology in transgenic mice.
Am J Pathol. 2010 Feb;176(2):870-80. doi: 10.2353/ajpath.2010.090452. Epub 2009 Dec 30.
3
Parahippocampal tau pathology in healthy aging, mild cognitive impairment, and early Alzheimer's disease.
Ann Neurol. 2002 Feb;51(2):182-9. doi: 10.1002/ana.10086.
4
Reduction of phosphorylated tau during memantine treatment of Alzheimer's disease.
Dement Geriatr Cogn Disord. 2007;24(4):247-52. doi: 10.1159/000107099. Epub 2007 Aug 14.
5
From tau to toxicity: emerging roles of NMDA receptor in Alzheimer's disease.
J Alzheimers Dis. 2006 Sep;10(1):81-7. doi: 10.3233/jad-2006-10112.
6
Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24-week, randomized, clinical trial.
J Clin Psychopharmacol. 2013 Oct;33(5):636-42. doi: 10.1097/JCP.0b013e31829a876a.
7
PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients.
J Prev Alzheimers Dis. 2020;7(4):256-264. doi: 10.14283/jpad.2020.6.
8
Polygenic hazard score: an enrichment marker for Alzheimer's associated amyloid and tau deposition.
Acta Neuropathol. 2018 Jan;135(1):85-93. doi: 10.1007/s00401-017-1789-4. Epub 2017 Nov 24.
9
Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type.
Arch Neurol. 2009 May;66(5):638-45. doi: 10.1001/archneurol.2009.55.
10
Phosphorylated tau sites that are elevated in Alzheimer's disease fluid biomarkers are visualized in early neurofibrillary tangle maturity levels in the post mortem brain.
Alzheimers Dement. 2023 Mar;19(3):1029-1040. doi: 10.1002/alz.12749. Epub 2022 Aug 3.
引用本文的文献
1
Stable cerebrospinal fluid neurogranin and β-site amyloid precursor protein cleaving enzyme 1 levels differentiate predementia Alzheimer's disease patients.
Brain Commun. 2022 Sep 24;4(5):fcac244. doi: 10.1093/braincomms/fcac244. eCollection 2022.
2
Increased Fear Memory and Glutamatergic Modulation in Compulsive Drinker Rats Selected by Schedule-Induced Polydipsia.
Front Behav Neurosci. 2019 May 7;13:100. doi: 10.3389/fnbeh.2019.00100. eCollection 2019.
3
Imaging and cerebrospinal fluid biomarkers in the search for Alzheimer's disease mechanisms.
Neurodegener Dis. 2014;13(2-3):163-5. doi: 10.1159/000355063. Epub 2013 Oct 2.
4
Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease.
Alzheimers Res Ther. 2010 Nov 30;2(6):32. doi: 10.1186/alzrt56.
本文引用的文献
1
Memantine protects rat cortical cultured neurons against beta-amyloid-induced toxicity by attenuating tau phosphorylation.
Eur J Neurosci. 2008 Nov;28(10):1989-2002. doi: 10.1111/j.1460-9568.2008.06498.x.
2
Treatment options in Alzheimer's disease: maximizing benefit, managing expectations.
Dement Geriatr Cogn Disord. 2008;25(5):408-22. doi: 10.1159/000122962. Epub 2008 Apr 3.
3
Hypometabolism and altered cerebrospinal fluid markers in normal apolipoprotein E E4 carriers with subjective memory complaints.
Biol Psychiatry. 2008 Mar 15;63(6):609-18. doi: 10.1016/j.biopsych.2007.05.030. Epub 2007 Aug 27.
4
Reduction of phosphorylated tau during memantine treatment of Alzheimer's disease.
Dement Geriatr Cogn Disord. 2007;24(4):247-52. doi: 10.1159/000107099. Epub 2007 Aug 14.
5
Longitudinal stability of CSF biomarkers in Alzheimer's disease.
Neurosci Lett. 2007 May 23;419(1):18-22. doi: 10.1016/j.neulet.2007.03.064. Epub 2007 Apr 6.
6
Potential role of N-methyl-D-aspartate receptors as executors of neurodegeneration resulting from diverse insults: focus on memantine.
Behav Pharmacol. 2006 Sep;17(5-6):411-24. doi: 10.1097/00008877-200609000-00007.
7
Alzheimer's disease.
Lancet. 2006 Jul 29;368(9533):387-403. doi: 10.1016/S0140-6736(06)69113-7.
8
Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults.
NeuroRx. 2004 Jan;1(1):101-10. doi: 10.1602/neurorx.1.1.101.
9
Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration.
FEBS Lett. 2004 May 21;566(1-3):261-9. doi: 10.1016/j.febslet.2004.04.047.
10
Paradigm shift in neuroprotective drug development: clinically tolerated NMDA receptor inhibition by memantine.
Cell Death Differ. 2004 Jan;11(1):18-20. doi: 10.1038/sj.cdd.4401344.
Zotero 插件